Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis

Leukocyte subtypes can be used to evaluate the severity of ulcerative colitis (UC). In this study, we examined the relationship between the lymphocyte-to-monocyte ratio (LMR) and the Mayo endoscopic score (MES) in assessing endoscopic activity in UC. Eighty-nine samples of leukocyte subtypes and biomarkers, including fecal calprotectin (FC), the fecal immunochemical occult blood test (FIT), and C-reactive protein (CRP), from 71 patients with UC were retrospectively investigated, along with the MES. The MES was significantly correlated with the LMR, FC, the FIT, and CRP. There were significant differences in the LMR, FC, the FIT, and CRP between groups with an MES < 1 and >2 (p = 0.001, p = 0.003, p < 0.001, and p < 0.001, respectively). In the receiver operating characteristic (ROC) analysis for predicting mucosal healing (MES 0 or 1), the areas under the curve (AUCs) for the LMR, FC, the FIT, and CRP, were 0.712, 0.860, 0.908, and 0.796, respectively. In the analysis of patients without immunomodulators, the correlation of the MES with the LMR and CRP was significant. The LMR can be used to assess endoscopic activity in UC, particularly in patients without immunomodulators.

• Publication year

  2021

• Venue

  Immuno

• Publication date

  2021-10-03

• Fields of study

  Not labeled

• Identifiers
  DOI 10.3390/immuno1040024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease

  2021cited by this paper
• The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis

  2020cited by this paper
• Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis

  2020cited by this paper
• Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

  2019influential reference
• Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity

  2019influential reference
• Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis

  2018cited by this paper
• Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders.

  2017cited by this paper
• Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?

  2016cited by this paper
• Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis

  2016cited by this paper
• Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test

  2015cited by this paper
• Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity

  2015cited by this paper
• Prostaglandin E–Major Urinary Metabolite as a Reliable Surrogate Marker for Mucosal Inflammation in Ulcerative Colitis

  2014cited by this paper
• Neutrophil–Lymphocyte Ratio as a Predictor of Disease Severity in Ulcerative Colitis

  2013cited by this paper
• Evaluation of Mucosal Healing of Ulcerative Colitis by a Quantitative Fecal Immunochemical Test

  2013cited by this paper
• Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

  2012cited by this paper
• Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity.

  2012cited by this paper
• Inflammatory bowel disease.

  2011cited by this paper
• Regulation of homeostasis and inflammation in the intestine.

  2011cited by this paper
• Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

  2011cited by this paper
• Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C‐reactive protein, and blood leukocytes

  2009cited by this paper
• Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

  1989influential reference
• Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

  1987cited by this paper
• The role of phagocytes in inflammatory bowel disease.

  1985cited by this paper
• Monocytes in inflammatory bowel disease: absolute monocyte counts.

  1980cited by this paper
• Impaired Lymphocyte Responsiveness in Inflammatory Bowel Disease

  1973cited by this paper

• No citing papers are available for this paper.